These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 7695281)
21. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Knapp CC; Sierra-Madero J; Washington JA Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423 [TBL] [Abstract][Full Text] [Related]
22. In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species. Edelstein PH; Edelstein MA Antimicrob Agents Chemother; 1994 Feb; 38(2):200-4. PubMed ID: 8192443 [TBL] [Abstract][Full Text] [Related]
23. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong. Ling TK; Ying CM; Lee CC; Liu ZK Med Princ Pract; 2005; 14(5):338-41. PubMed ID: 16103700 [TBL] [Abstract][Full Text] [Related]
24. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases. Bonomo RA; Rudin SA; Shlaes DM FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111 [TBL] [Abstract][Full Text] [Related]
25. In vitro activity of YTR 830. Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029 [TBL] [Abstract][Full Text] [Related]
26. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units. Gill CJ; Ponticas S; Shungu DL; Guerriero S Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725 [TBL] [Abstract][Full Text] [Related]
27. Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis. Tweardy DJ; Jacobs MR; Speck WT J Antimicrob Chemother; 1983 Aug; 12(2):133-9. PubMed ID: 6555189 [TBL] [Abstract][Full Text] [Related]
28. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients. Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972 [TBL] [Abstract][Full Text] [Related]
29. In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. Verhaegen J; Verbist L J Antimicrob Chemother; 1998 Mar; 41(3):381-5. PubMed ID: 9578165 [TBL] [Abstract][Full Text] [Related]
30. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. Akova M; Yang Y; Livermore DM J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496 [TBL] [Abstract][Full Text] [Related]
35. Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes. Aldridge KE; Morice N; Schiro DD Diagn Microbiol Infect Dis; 1994 Aug; 19(4):227-34. PubMed ID: 7851086 [TBL] [Abstract][Full Text] [Related]
36. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae. Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705 [TBL] [Abstract][Full Text] [Related]
37. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. Livermore DM; Yuan M J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716 [TBL] [Abstract][Full Text] [Related]
38. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. Pankuch GA; Jacobs MR; Appelbaum PC J Antimicrob Chemother; 1995 Jun; 35(6):883-8. PubMed ID: 7559200 [TBL] [Abstract][Full Text] [Related]
39. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro]. Zhao C; Xie W; Zhang W; Ye Z; Wu H Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663 [TBL] [Abstract][Full Text] [Related]
40. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams. Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]